Clinical Trial Update: A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating mis-matched immune cells (AlloStim) in patients with advanced hematological malignancies; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancy
• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• AlloStim (allogeneic immunotherapy)

Snippet

Sponsor: Mirror Biologics, Inc. | Conditions: Hematological Malignancy, Leukemia | Phase 1, Phase 2 | Status: COMPLETED